The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical
problem. Although many drivers of acquired drug resistance have been identified,,–, the …

Checkpoint immunotherapy holds great potential to treat malignancies via blocking the
immunosuppressive signaling pathways, which however suffers from inefficiency and off …

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

SHP2 mediates the activities of multiple receptor tyrosine kinase signaling and its function in
endothelial processes has been explored extensively. However, genetic studies on the role …

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …

Phosphorylation is a reversible post-translational modification regulated by phosphorylase
and dephosphorylase to mediate important cellular events. Src homology-2-containing …